Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The document explains breast development, common breast conditions, and their treatments.

This case report found that a patient with cutaneous polyarteritis nodosa experienced rare and severe manifestations, including digital gangrene and a breast ulcer, requiring aggressive treatment and resulting in below-knee amputation.

This review describes oncotherapy-induced alopecia in patients receiving hormone therapy for hormone-receptor-positive breast cancer and concludes that topical hormones should not be used due to oncogenic potential.

This study found that in female breast cancer patients, supplementation with 400 mg IND02 (Cinnamon bark extract) thrice daily during chemotherapy significantly reduced severe weight loss and hair loss compared to placebo, with the treatment being well-tolerated and safe.

This study found significant racial and ethnic disparities in the incidence and psychological impact of chemotherapy-related alopecia, with Asian women experiencing the greatest burden, highlighting the need for personalized and culturally sensitive care.

Recognizing specific scalp patterns can help diagnose hair loss linked to breast cancer spread.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

This study found no evidence of subtype-specific breast cancer risk associated with hair relaxer use among women in Ghana, though the risk was elevated for former users across all subtypes.

In this study, the combination of scalp cooling therapy and a scalp lotion containing DHL-HisZnNa demonstrated a 91.3% hair recovery rate among breast cancer patients undergoing certain chemotherapy regimens, with no serious adverse events reported.

This study found that Slovak breast cancer survivors experience moderate overall quality of life, with variations across domains linked to treatment types and sociodemographic factors, pointing to the need for tailored supportive care.

This case report highlights a potential link between silicone breast implants and autoimmune/inflammatory syndrome induced by adjuvants, suggesting explantation may help improve symptoms.

This study found that both scalp cooling systems and chemical cooling caps effectively reduced chemotherapy-induced alopecia in early breast cancer patients, with scalp cooling showing better early efficacy but chemical cooling providing greater psychological and quality of life benefits.

In this cross-sectional study, social support was found to improve empowerment and alopecia-related quality of life in breast cancer patients, with an indirect benefit on quality of life achieved through enhanced empowerment.

This review addresses the lack of clarity regarding safe hair loss treatments for breastfeeding women, emphasizing the importance of understanding medication transfer to breast milk and potential neonatal adverse effects.

Among transgender men, this study reported a case of breast cancer found incidentally after a gender-affirming mastectomy, despite common lower breast cancer risks in this population, highlighting the importance of cancer screening and careful consideration of hormone therapy management in transgender and gender-diverse individuals.

This study found that many young women with breast cancer experience a poor quality of life over time, especially regarding sexual health, future perspective, and hair loss.

This study found that alopecia induced by CDK4/6 inhibitors in breast cancer patients occurs more quickly and is more resistant to minoxidil treatment compared to endocrine therapy-induced alopecia.

This literature review reports prevalent sexual dysfunctions, notably vaginal dryness, in women undergoing endocrine therapy for hormone-dependent breast cancer, highlighting the need for more multidisciplinary research and care to improve patient well-being.

This analysis found that spironolactone use is not associated with an increased risk of breast cancer recurrence in female survivors.

This study will investigate the efficacy of YH0618 granules on reducing chemotherapy-induced hair loss in breast cancer patients, focusing on potential mechanisms related to kidney deficiency, with outcomes not yet reported.

This study aims to evaluate the efficacy of the traditional Chinese medicine YH0618 granule for reducing chemotherapy-induced hair loss in breast cancer patients through a double-blind, randomized clinical trial, assessing hair loss progression and improving quality of life markers compared to a placebo.

This study aims to assess the effectiveness of the YH0618 granule in reducing chemotherapy-induced hair loss in breast cancer patients, without disrupting anti-tumor effects, by conducting a randomized, double-blind trial. Results are not reported in the abstract.

This case report details a patient with lichen planopilaris who maintained successful hair transplant results for seven years, suggesting chemotherapy may have played a role in preventing re-activation of the disease.

This article summarizes the ACS/ASCO Breast Cancer Survivorship Care Guidelines, which address the physical and psychosocial long-term effects of breast cancer treatments and recommend management strategies for improving women's quality of life.

This study highlights a paradox where valproic acid, known for causing hair loss, may also promote hair growth when applied topically.

This review discusses the paradoxical effects of valproic acid on hair, noting that it can both cause alopecia and stimulate hair growth, but reports no new experimental findings.

This article discusses the paradoxical effects of valproic acid on hair, reporting both drug-induced hair loss and the potential for hair growth when used topically, but presents no original research findings.

This study examines hair loss rates during pregnancy and lactation, suggesting a connection between hair loss and unmet daily nutritional requirements.

Long-term use of oral contraceptives, especially starting before age 20, may increase the risk of early-onset breast cancer.

In this review, the authors reported that past concerns linking spironolactone to an increased risk of breast cancer are unfounded, citing recent studies that confirm no such association, indicating spironolactone's potential as a treatment for alopecia in women without fear of cancer recurrence.